Coherus BioSciences Earnings Calls
Release date | May 12, 2025 |
EPS estimate | -$0.310 |
EPS actual | -$0.350 |
EPS Surprise | -12.90% |
Revenue estimate | 60.964M |
Revenue actual | 7.599M |
Revenue Surprise | -87.54% |
Release date | Mar 10, 2025 |
EPS estimate | -$0.100 |
EPS actual | -$0.280 |
EPS Surprise | -180.00% |
Revenue estimate | 60M |
Revenue actual | 54.144M |
Revenue Surprise | -9.76% |
Release date | Nov 06, 2024 |
EPS estimate | -$0.100 |
EPS actual | -$0.0100 |
EPS Surprise | 90.00% |
Revenue estimate | 43.877M |
Revenue actual | 70.774M |
Revenue Surprise | 61.30% |
Release date | Aug 08, 2024 |
EPS estimate | -$0.210 |
EPS actual | -$0.140 |
EPS Surprise | 33.33% |
Revenue estimate | 61.37M |
Revenue actual | 64.979M |
Revenue Surprise | 5.88% |
Last 4 Quarters for Coherus BioSciences
Below you can see how CHRS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Aug 08, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $1.29 |
EPS estimate | -$0.210 |
EPS actual | -$0.140 |
EPS surprise | 33.33% |
Date | Price |
---|---|
Aug 02, 2024 | $1.35 |
Aug 05, 2024 | $1.32 |
Aug 06, 2024 | $1.33 |
Aug 07, 2024 | $1.24 |
Aug 08, 2024 | $1.29 |
Aug 09, 2024 | $1.43 |
Aug 12, 2024 | $1.46 |
Aug 13, 2024 | $1.44 |
Aug 14, 2024 | $1.37 |
4 days before | -4.44% |
4 days after | 6.20% |
On release day | 10.85% |
Change in period | 1.48% |
Release date | Nov 06, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $0.724 |
EPS estimate | -$0.100 |
EPS actual | -$0.0100 |
EPS surprise | 90.00% |
Date | Price |
---|---|
Oct 31, 2024 | $0.745 |
Nov 01, 2024 | $0.723 |
Nov 04, 2024 | $0.670 |
Nov 05, 2024 | $0.731 |
Nov 06, 2024 | $0.724 |
Nov 07, 2024 | $0.82 |
Nov 08, 2024 | $0.82 |
Nov 11, 2024 | $0.779 |
Nov 12, 2024 | $0.82 |
4 days before | -2.85% |
4 days after | 13.77% |
On release day | 13.29% |
Change in period | 10.54% |
Release date | Mar 10, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $1.04 |
EPS estimate | -$0.100 |
EPS actual | -$0.280 |
EPS surprise | -180.00% |
Date | Price |
---|---|
Mar 04, 2025 | $1.05 |
Mar 05, 2025 | $1.03 |
Mar 06, 2025 | $1.00 |
Mar 07, 2025 | $1.04 |
Mar 10, 2025 | $1.04 |
Mar 11, 2025 | $1.05 |
Mar 12, 2025 | $0.98 |
Mar 13, 2025 | $0.89 |
Mar 14, 2025 | $0.92 |
4 days before | -0.95% |
4 days after | -11.53% |
On release day | 0.96% |
Change in period | -12.37% |
Release date | May 12, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $1.02 |
EPS estimate | -$0.310 |
EPS actual | -$0.350 |
EPS surprise | -12.90% |
Date | Price |
---|---|
May 06, 2025 | $0.93 |
May 07, 2025 | $0.95 |
May 08, 2025 | $0.99 |
May 09, 2025 | $0.97 |
May 12, 2025 | $1.02 |
May 13, 2025 | $0.83 |
May 14, 2025 | $0.790 |
May 15, 2025 | $0.768 |
May 16, 2025 | $0.761 |
4 days before | 9.69% |
4 days after | -25.39% |
On release day | -19.11% |
Change in period | -18.16% |
Coherus BioSciences Earnings Call Transcript Summary of Q1 2025
Coherus BioSciences Q1 2025 Earnings Call Summary for Investors
Key Highlights:
- Transition to Innovative Oncology Focus:
- Coherus has completed its biosimilar divestitures and is now focusing on its innovative oncology pipeline, particularly the PD-1 inhibitor LOQTORZI and related proprietary products.
- LOQTORZI Performance:
- LOQTORZI, an FDA-approved PD-1 inhibitor for metastatic recurrent nasopharyngeal carcinoma (NPC), is projected to generate $150 million to $200 million in annual sales over the next three years.
- The company expects to cover commercial and R&D costs once quarterly revenues surpass $15 million.
- Commercial Strategy:
- A recent restructuring of the sales force is complete, aimed at enhancing market penetration and education about LOQTORZI.
- Demand for LOQTORZI grew by 15% in Q1, with positive feedback from physicians leading to increased patient starts.
- The new NCCN guidelines position LOQTORZI as a preferred treatment in combination with chemotherapy, which the company is actively promoting to oncologists.
- Pipeline Developments:
- Toripalimab (LOQTORZI): The company intends to expand its indications by working on combination therapies with other agents and collaborations with various partners.
- CHS-114 (CCR8 cytolytic antibody) is progressing, with initial data suggesting it effectively depletes Tregs in the tumor microenvironment, which is promising for treating solid tumors.
- Casdozokitug (anti-IL-27) is being evaluated in combination therapies for hepatocellular carcinoma and non-small cell lung cancer, with data expected in the first half of 2026.
- Financial Overview:
- Revenue from LOQTORZI was stable at $7.3 million; however, ongoing operational improvements are expected to enhance growth.
- The divestiture of UDENYCA is complete, providing Coherus with $483 million in upfront cash, and significant savings are anticipated from reduced headcount and operational costs.
- The company expects to have about $200 million in net cash after the recent divestiture and plans to further repurchase convertible notes.
- Investment Strategy:
- Coherus is positioned to leverage its unique profiling of LOQTORZI and ongoing pipeline advancements to generate revenue.
- The focus is also on maintaining and expanding partnerships for clinical trials and indication expansion that require minimal upfront costs for Coherus.
Conclusion:
Coherus BioSciences is transitioning into a commercial-stage innovative oncology firm, with a clear strategy to enhance the reach and impact of its lead product, LOQTORZI. With a supportive market environment and planned initiatives, Coherus is focused on driving growth and expanding its pipeline opportunities. Investors should monitor upcoming data releases and trial outcomes that could significantly impact the company’s valuation and market position.